Integrated CBT to Improve Functioning in Veterans With Anxiety and Substance Use

Sponsor
VA Office of Research and Development (U.S. Fed)
Overall Status
Not yet recruiting
CT.gov ID
NCT04871100
Collaborator
(none)
40
1
2
47.9
0.8

Study Details

Study Description

Brief Summary

Individual with anxiety and post-traumatic stress disorder often use alcohol in ways that could cause them harm. Treating both mental health concerns and alcohol use at the same time can help reduce difficulties engaging in multiple treatments. The investigators are evaluating how a cognitive behavioral therapy program that helps Veterans with anxiety, posttraumatic stress disorder, and alcohol use at the same time can help improve the participants lives.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Unified Protocol- Alcohol
  • Behavioral: Problem Solving therapy
Early Phase 1

Detailed Description

Co-occurring hazardous drinking, anxiety disorders, and PTSD are problematic combinations of mental health concerns experienced by deployed Veterans. Veterans who have been deployed are at particular risk for experiencing problems in functioning and reintegration related to mental health disorders and hazardous drinking. Co-occurring anxiety and hazardous drinking heavily impact psychosocial functioning and quality of life. Although cognitive behavior therapy (CBT) can promote psychological recovery through improvements in functioning and quality of life, most CBT protocols do not address co-occurring disorders, leading to inefficient and disjointed treatment. The current research seeks to adapt and test the Unified Protocol (UP) for deployed Veterans with hazardous drinking. The use of combined CBT for both anxiety disorders and hazardous drinking has the potential to more efficiently and effectively improve functioning, reduce symptoms, and promote psychosocial recovery.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Participants will be randomized to receive the intervention or a control intervention.Participants will be randomized to receive the intervention or a control intervention.
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Addressing Mental Health Comorbidities: Integrated CBT to Improve Functioning in Veterans With Co-Occurring Anxiety and Substance Use
Anticipated Study Start Date :
Oct 3, 2022
Anticipated Primary Completion Date :
Oct 1, 2025
Anticipated Study Completion Date :
Oct 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: UP-A

Cognitive behavior therapy using the Unified Protocol for Emotional Disorders with supplemental skills-based alcohol modules.

Behavioral: Unified Protocol- Alcohol
Transdiagnostic cognitive behavior therapy for emotional disorders modified to include CBT for alcohol use.

Active Comparator: Problem Solving therapy

Skills based approach for managing negative moods and stress.

Behavioral: Problem Solving therapy
Skills based approach for managing negative moods and stress.

Outcome Measures

Primary Outcome Measures

  1. Social Adjustment Scale- Self Report [2-weeks]

    Evaluates individuals' satisfaction with social situation. Greater scores reflect greater social/occupational impairment (range 42-210).

  2. Beck Anxiety Inventory [past 30 days]

    Evaluates levels of anxiety in past month. Higher scores reflect greater anxiety (range 0-63).

  3. Addiction Severity Index [30 days]

    Assessment of substance use and related problems. Higher scores in each domain indicate problems related to substance use in that domain (range for each domain 0-1).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • meeting diagnostic criteria for current anxiety disorder and

  • endorsing hazardous alcohol use

Exclusion Criteria:

-need for acute medically-supervised detoxification with exclusionary criteria of

  • high-risk suicidality

  • psychotic symptoms, or

  • cognitive impairment that could interfere with engagement in weekly psychotherapy

Contacts and Locations

Locations

Site City State Country Postal Code
1 Michael E. DeBakey VA Medical Center, Houston, TX Houston Texas United States 77030

Sponsors and Collaborators

  • VA Office of Research and Development

Investigators

  • Principal Investigator: Anthony Ecker, PhD, Michael E. DeBakey VA Medical Center, Houston, TX

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
VA Office of Research and Development
ClinicalTrials.gov Identifier:
NCT04871100
Other Study ID Numbers:
  • D3520-W
  • 1IK2RX003520-01A2
First Posted:
May 4, 2021
Last Update Posted:
Apr 14, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by VA Office of Research and Development
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 14, 2022